LFWD

Lifeward Ltd.

$5.84

-5.42%
SectorHealthcareIndustryMedical DevicesCountryIsrael

Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals' post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as ReWalk Robotics Ltd. and changed its name to Lifeward Ltd. in September 2024.

Source: Yahoo Finance
AI summary

Price & performance

1M-14.5%
3M-16.8%
YTD-21.1%
1Y-25.3%
52-week range—
Beta1.18
Full chart and returns against a benchmark

Q-Score

25/ 100

Quality against peers; 50 is the peer median.

Growth26
Risk38
Performance29
Valuation24
Profitability32
Leverage46
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$1.4M-17.6%
Net income-$19.9M
Net margin—
Historical fundamentals

Red flags in filings

3active red flags
Going-concern doubtMar 18, 2026
Late filing noticeMay 15, 2026
Exchange listing noticeMar 20, 2026
Filings, findings and the timeline

Revenue exposure

40%of revenue from outside the US
United States60%
Germany18%
Other countries13%
Largest customer15%
Regions, segments, customers and suppliers

Valuation

LFWDIndustryP/E—29.61P/S13.703.49EV/EBITDA—18.38P/B1.363.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 12next report
EPS estimate$-1.04
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate